参考文献/References:
[1]赵坤,姚型锋.自体DC-CIK免疫疗法治疗晚期非小细胞肺癌的临床研究[J].现代肿瘤医学,2015(5):56-68. [2]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2016,65(2):87-108. [3]朱猛,程阳,戴俊程,等.基于全基因组关联研究的中国人群肺癌风险预测模型[J].中华流行病学杂志,2016,36(10):1047-1052. [4]Wang J,Jia Y,Zhao S,et al.BIN1 reverses PD－L1－mediated immune escape by inactivating the c－MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer[J].Oncogene,2017,36(45):6235-6243. [5]任军龙,薛磊,孙光远,等.胸腔镜下肺癌根治术治疗早期非小细胞肺癌临床观察[J].山东医药,2015(23):48-50. [6]Lu YC,Parker LL,Lu T,et al.Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3[J].J Clin Oncol,2017,35(29):3322-3329. [7]周立新,关鸿志,刘洪生,等.小细胞肺癌相关神经副肿瘤综合征的临床特点及治疗[J].中华医学杂志,2015,95(37):3023-3026. [8]邹游.周期诱导联合化疗后耐药肿瘤细胞亚群与肿瘤干细胞相关性的研究[D].华中科技大学,2011. [9]Antonia S,Goldberg SB,Balmanoukian A,et al.Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer:a multicentre,phase 1b study[J].Lancet Oncol,2016,17(3):299-308. [10]Butts C,Socinski MA,Mitchell PL,et al.Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial[J].Lancet Oncol,2014,15(1):59-68. [11]Antonia SJ,Villegas A,Daniel D,et al.Dur valumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J].N Engl J Med,2017,377(20):1919-1929. [12]Gunturi A,Mcdermott D F.Nivolumab for the treatment of cancer[J].Expert Opinion on Investigational Drugs,2015,24(2):253-260. [13]赵静,苏春霞.《CSCO免疫检查点抑制剂相关的毒性管理指南》解读:对比NCCN免疫治疗相关毒性管理指南[J].实用肿瘤杂志,2020,35(1):11-15. [14]Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus docetaxelin advanced squamous cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135. [15]张曼,杨涛,石洋,等.DCs-CIK细胞免疫治疗联合化疗对晚期非小 细胞肺癌疗效及安全性的影响[J].肿瘤,2016,34(4):361-365. [16]邓旭,吴昌平,卢斌峰,等.免疫卡控点程序性死亡分子-1配体/程序性死亡分子-1在肿瘤免疫治疗中的作用机制[J].中华实验外科杂志,2015,32(4):934-936. [17]Hellmann MD,Rizvi NA,Goldman JW,et al.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer(CheckMate 012):results of an open-label,phase 1,multicohort study[J].Lancet Oncol,2017,18(1):31-41. [18]苏强,闫涵,侯艳丽,等.PD-1－1／PD-L1抗体与多西他赛治疗晚期非小细胞肺癌安全性[J].中华肿瘤防治杂志,2016,23(3):1450-1454. [19]Gettinger S,Rizvi NA,Chow LQ,etal.Nivolumab monotherapy forfirst-line treatment of advanced non-small-cell lung cancer[J].J Clin Oncol,2016,34(25):2980-2987. [20]Reck M,D Rodríguez-Abreu,Robinson AG,et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J].New England Journal of Medicine,2016,375(19):1823. [21]彭小星.靶向同步放疗治疗老年肺癌30例[J].中国老年学杂志,2016,32(23):5305-5306. [22]霍飞,张蕊.1996~2015年吸烟与肺癌国际研究状况文献计量学分析[J].中国慢性病预防与控制,2016,24(6):477. [23]Gettinger SN,Shepherd FA,Antonia SJ,et al.First-line nivolum-ab(anti-PD-1BMS-936558,ONO-4538)monotherapy inadvanced NSCLC:Safety,efficacy,and correlation of outcomeswith PD-L1 status[J].J Clin Oncol,2016,32(15):8124. [24]Ferrara R,Imbimbo M,Malouf R,et al.Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer[J].Cochrane Database Syst Rev,2020(12):CD013257.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]李书有.中晚期肝癌的非手术综合治疗[J].医学信息,2022,35(09):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
LI Shu-you.Non-surgical Comprehensive Treatment for Advanced Liver Cancer[J].Medical Information,2022,35(11):73.[doi:10.3969/j.issn.1006-1959.2022.09.018]
[3]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[4]张 慧,胡广越,殷 红.菌群干预与免疫治疗的研究进展[J].医学信息,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
ZHAHG Hui,HU Guang-yue,YIN Hong.Research Progress in Microbial Intervention and Immunotherapy[J].Medical Information,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
[5]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(11):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[6]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(11):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[7]陈 旸,曾 川,张献全.肝细胞肝癌的靶向及免疫治疗研究现状与进展[J].医学信息,2019,32(03):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
CHEN Yang,ZENG Chuan,ZHANG Xian-quan.Current Status and Progress of Research on Hepatocellular Carcinoma Targeting and Immunotherapy[J].Medical Information,2019,32(11):45.[doi:10.3969/j.issn.1006-1959.2019.03.015]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(11):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(11):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[10]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[11]刘 垚,钱有辉.ctDNA检测及靶向药物在非小细胞肺癌中的应用[J].医学信息,2020,33(11):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
LIU Yao,QIAN You-hui.Detection of ctDNA and Application of Targeted Drugs in Non-small Cell Lung Cancer[J].Medical Information,2020,33(11):38.[doi:10.3969/j.issn.1006-1959.2020.11.013]
[12]侯晓杰.免疫治疗药物对非小细胞肺癌的有效性和安全性研究[J].医学信息,2022,35(18):118.[doi:10.3969/j.issn.1006-1959.2022.18.032]
HOU Xiao-jie.Study on the Efficacy and Safety of Immunotherapy Drugs for Non-small Cell Lung Cancer[J].Medical Information,2022,35(11):118.[doi:10.3969/j.issn.1006-1959.2022.18.032]
[13]韩 寒,陈雨晨,刘 洋,等.替雷利珠单抗治疗晚期非小细胞肺癌患者的真实世界研究[J].医学信息,2025,38(08):80.[doi:10.3969/j.issn.1006-1959.2025.08.016]
HAN Han,CHEN Yuchen,LIU Yang,et al.A Real-world Study of Tislelizumab in the Treatment of Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2025,38(11):80.[doi:10.3969/j.issn.1006-1959.2025.08.016]